Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

Anticoagulants Market Summary

Significant advancements in the formulation of novel anticoagulants, growing utilization by health professionals to reduce serious health complications, and innovations such as direct-acting oral anticoagulants (DOACs) fuel growth for this market.

In recent years, rising venous thromboembolism (VTE) has been recorded across regions. According to the U.S. Center for Disease Control and Prevention (CDC), in the U.S., up to 900,000 individuals are affected by it each year. CDC also states that nearly 60,000-100,000 fatalities are caused by venous thromboembolism (VTE) every year. Health professionals prefer using anticoagulants to prevent thromboembolic events and complications such as strokes. These aspects are likely to generate significant growth in demand in this market.

A sedentary lifestyle, increasing urbanization, changing dietary preferences, and a lack of physical activity have contributed to the growing number of individuals experiencing cardiovascular diseases. VTE is also linked with multiple other conditions, including cancer, complicated surgeries, pregnancy, and others. According to the CDC, VTE is one of the leading causes of preventable hospital demises in the U.S. Such aspects are expected to result in continuous growth in adopting anticoagulants.

Recent advancements in healthcare technology related to anticoagulants are anticipated to assist the market in growing. For instance, in February 2024, Roche (F. Hoffmann-La Roche Ltd) launched novel Factor Xa inhibitor coagulation tests designed to facilitate clinical decisions to prescribe direct oral anticoagulants, primarily for stroke prevention. Furthermore, the increasing incidence of stroke is projected to propel the market growth during the forecast period. Blood thinners are used for stroke prevention in individuals at risk due to various conditions, such as atrial fibrillation, certain heart valve disorders, and previous strokes. As per the CDC, over 795,000 individuals in the U.S. experience stroke every year, out of which approximately 610,000 are first-time or new strokes. 

Market Concentration & Characteristics

The market growth stage is moderate, and the market growth is accelerating. The market experiences a high degree of innovation driven by advancements in multiple areas of the healthcare industry. For example, advances in pharmacogenomics allow for more personalized anticoagulant therapy. Increasing availability and access to point-of-care diagnostic devices and home monitoring kits have enabled patients to monitor their coagulation status conveniently. The emergence of modern technologies such as AI and integration with medical devices have also developed key advancements in the detection and analysis of blood clotting.

Pharmaceutical companies engage in M&A activities to expand their product portfolios and enter new therapeutic areas. Acquiring or merging with companies with novel drug candidates or established products can be a strategic move to diversify offerings. Companies pursue M&A to access innovative anticoagulant development, formulation, or drug delivery technologies. This can enhance their research and development capabilities, potentially leading to the introduction of more advanced anticoagulant therapies. For instance, in February 2025, Novartis has announced that it has agreed to acquire Anthos Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Boston, U.S. Anthos has been developing abelacimab, a late-stage drug designed for preventing stroke and systemic embolism, particularly in patients with atrial fibrillation.

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies, have set stringent standards for the approval and registration of anticoagulant drugs. The regulatory process involves extensive preclinical and clinical trials to demonstrate the safety and efficacy of new anticoagulant therapies. Hospitals are major end users of anticoagulant therapies, particularly for acute conditions such as DVT, pulmonary embolism, and post-surgical prophylaxis. Ambulatory care centers, including specialized anticoagulation clinics, contribute to end-user concentration by providing targeted anticoagulation management services. These centers often focus on monitoring and adjusting anticoagulant therapy, ensuring patient adherence, and preventing complications.

Drug Category Insights

Based on the drug category, the Novel Oral Anticoagulants (NOACs) segment dominated the global anticoagulants industry with a revenue share of 57.2% in 2024. Growing awareness regarding the benefits associated with the adoption of NOACs is primarily driving growth. Benefits of NOACs include minimal drug interaction, a broader therapeutic window, fixed daily doses, and others. The growth of the segment is attributed to the rising adoption of NOACs in developing countries as the preferred option over warfarin owing to its effectiveness and safety.

New drug approvals, product launches, and research-driven product developments will likely influence this market's growth in the forecast period. For instance, in February 2025, TRIASTEK announced it had received Investigational New Drug (IND) clearance for T20G. In 2024, T20G, a proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product by TRIASTEK, was given IND clearance by China's National Medical Products Administration (NMPA)-the role of anticoagulation therapy in therapeutic interventions linked with stroke prevention in cases related with atrial fibrillation.

Heparin segment is projected to experience significant growth over the forecast period. The indications for heparin and Low Molecular Weight Heparin (LMWH) are expanding into acute treatment to include prevention in high-risk patients, such as those undergoing major surgery or experiencing prolonged immobilization. The increasing prevalence of thrombotic events fuels the demand for heparin and LMWH. Furthermore, heparin and LMWH are often considered cost-effective anticoagulant options, especially in resource-limited healthcare settings. The affordability and effectiveness of these agents make them attractive choices in various healthcare systems globally.

Route Of Administration

Oral anticoagulants held the largest revenue share of the global anticoagulants industry in 2024. Growth of this segment is primarily driven by the increasing adoption of Novel Oral Anticoagulants (NOACs), ease of use, and growing availability. Oral anticoagulants offer a convenient and patient-friendly alternative to traditional injectable forms. This is particularly crucial for long-term therapy, where patient adherence to the prescribed treatment regimen is essential. The ease of administration contributes significantly to the overall preference for oral anticoagulants among healthcare providers and patients. Increasing research and development activities driven by exploring novel anticoagulants that can target Factor XI and FXIa, to prevent thrombosis while eliminating negative impact on hemostasis, is expected to generate lucrative growth.

Based on route of administration, the injectable anticoagulants segment is anticipated to experience growth from 2025 to 2030. The segment's growth is due to its increasing use in treating various medical conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation. These anticoagulants are administered through injections and have a quicker onset of action than oral anticoagulants. Additionally, the prevalence of chronic conditions such as atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE) is increasing globally. These conditions require anticoagulant therapy to prevent blood clots, which can lead to serious complications such as stroke and heart attack. These factors are expected to support the injectable anticoagulants segment in the forecast years.

Application Insights

The Atrial Fibrillation/Myocardial Infarction (Heart Attack) segment dominated the global anticoagulants industry in 2024. Atrial fibrillation is a common heart condition that can lead to blood clots and stroke, and anticoagulants are an effective treatment option for reducing the risk of these complications. New product launches and recent approvals by regulatory authorities are also expected to drive the growth of this segment. For instance, in February 2025, the Central Drugs Standard Control Organization, a regulatory authority in India, approved Edoxaban 15, 30, and 60 mg tablets designed for the prevention of systemic embolism and stroke in adult patients with Nonvalvular Atrial Fibrillation (Nvaf). Such developments are expected to generate greater adoption in cases of patients having more than one risk factor, such as Transient Ischaemic Attack (Tia), hypertension, Congestive Heart Failure, and others.

Deep Vein Thrombosis (DVT) is anticipated to experience significant growth over the forecast period. The growth of this segment is mainly driven by the growing prevalence of DVT and the increasing geriatric population that is more prone to DVT. The use of anticoagulants assists patients in slowing down the growth of existing blood clots and preventing the formation of new clots. Anticoagulants enable the fibrinolytic system and support the dissolving of blood clots. Significantly growing incidence of DVT across multiple regions is expected to drive the growth of this segment.

Regional Insights

North America dominated the global anticoagulants industry with revenue share of 51.2% in 2024. A large number of patients in the region regularly use anticoagulants. The presence of multiple biopharmaceutical companies in the region, significant innovations linked with the inclusion of anticoagulation therapy in the treatment of venous thromboembolism (VTE), and ongoing research and development efforts by major market participants are expected to create notable opportunities for this market.

U.S. Anticoagulants Market Trends

The U.S. anticoagulants market dominated the regional industry with a revenue share of 85.8% in 2024. The sophisticated healthcare ecosystem in the country, multiple anticoagulant manufacturers and marketers operating in the U.S., and numerous companies' focus on effectively distributing their products in the U.S. market are some of the key growth drivers. Many patients with cardiovascular diseases, especially those aged 60 and more, are likely to fuel demand for this market.

Europe Anticoagulants Market Trends

Europe was identified as one of the key regions of global anticoagulants industry in 2024. Some of the key growth drivers for this market include sedentary lifestyles, significant growth in individuals with cardiovascular diseases, and growing patients who experience pulmonary embolism. Advancements in diagnosing and managing pulmonary embolism to prevent fatal consequences are expected to fuel growth in Europe.

Asia Pacific Anticoagulants Market Trends

Asia Pacific anticoagulants market is anticipated to grow at the fastest CAGR of 6.1% during the forecast period. The growth of this market is mainly driven by the presence of highly populated countries such as China and India, the increasing number of patients experiencing cardiovascular diseases, and the focus of multiple pharmaceutical brands to improve their presence in the region. Growing awareness regarding risks associated with vascular thrombosis is expected to drive the demand for anticoagulants in this regional market.

The Japan anticoagulants market held the largest revenue share of the Asia Pacific anticoagulants industry in 2024. This is attributed to growing demand driven by the large number of patients with cardiovascular diseases and the country's increasing geriatric population. In 2023, nearly 30.0% of the population was aged 65 and above in Japan. Increasing awareness regarding the role of novel anticoagulants in preventing blood clots is expected to drive the growth of this market.

Key Anticoagulants Company Insights

Some of the key companies operating in the global anticoagulants industry are Aspen Holdings, Pfizer Inc., Sanofi, Bristol-Myers Squibb Company, Bayer AG and others. Major market participants have been embracing strategies such as new product development, innovation-based product launches, improved investment in research, and collaborations with other organizations.

• Aspen Holdings is a pharmaceutical company specializing in marketing and manufacturing a wide range of post-patent, branded medicines. It offers injectable products, prescriptions, and OTC medicines. Its product range linked with thrombosis includes Arixtra, Fraxiparine, Fraxodi, and others.

• Pfizer Inc., one of the major market participants in the biopharmaceuticals industry offers a variety of anticoagulation products, including a novel oral anticoagulant (NOAC), Eliquis (apixaban). It also provides Heparin Sodium Injection in various forms, including IV bags, vials, and syringes.

Recent Developments

• In December 2024, Novo Nordisk announced its Alhemo (concizumab-mtci) injection announced approval from the U.S. Food and Drug Administration (FDA). The approval is expected to strengthen its portfolio and further its commitment to offering solutions for rare bleeding disorders.

• In October 2024, Pfizer Inc. announced that it had received U.S. FDA approval for its HYMPAVZI (marstacimab-hncq), developed for treating Hemophilia A or B without inhibitors. It is a once-weekly subcutaneous prophylactic treatment.

• In November 2023, Pharmascience Canada announced the launch of the generic drug (Pr) pms-RIVAROXABAN. This medicine belongs to the anticoagulant (blood thinner) group and helps prevent blood clots by directly blocking the activity of Factor Xa.

• In July 2023, Endo International plc. launched bivalirudin injection in ready-to-use (RTU) vials in the U.S. with the collaboration of Gland Pharma Limited, India, and MAIA Pharmaceuticals, Inc. The new RTU vials of bivalirudin are expected to be more convenient and efficient for healthcare professionals.

Anticoagulants Market Report Scope

Global Anticoagulants Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global anticoagulants market report based on drug category, route of administration, application, and region:

• Drug Category Outlook (Revenue, USD Million; 2018 - 2030)

  • Novel Oral Anticoagulants (NOACs)

    • Eliquis

    • Xarelto

    • Savaysa & lixiana

    • Pradaxa

  • Vitamin K Antagonist

  • Direct Thrombin Inhibitors

  • Heparin

    • Type

      • Low Molecular Weight Heparin

      • Ultra-low Molecular Weight Heparin

      • Unfractionated Heparin

    • Source

      • Porcine

      • Bovine

      • Others

  • Others

• Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)

  • Oral Anticoagulants

  • Injectable Anticoagulants

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Atrial Fibrillation/Myocardial Infarction (Heart Attack)

  • Deep Vein Thrombosis (DVT)

  • Pulmonary Embolism

  • Other Applications

• Regional Outlook (Revenue, USD Billion; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait